Amicus Therapeutics Stock Cash Flow From Operations

FOLD Stock

USD 8.62 0.07 0.81%

Amicus Therapeutics fundamentals help investors to digest information that contributes to Amicus Therapeutics' financial success or failures. It also enables traders to predict the movement of Amicus Stock. The fundamental analysis module provides a way to measure Amicus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amicus Therapeutics stock.

Total Liab Other Stockholder Equity

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Amicus Therapeutics Company Cash Flow From Operations Analysis

Amicus Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Operating Cash Flow

EBITDA

-

Taxes

More About Cash Flow From Operations | All Equity Analysis

Current Amicus Therapeutics Cash Flow From Operations

(33.89 M)

Most of Amicus Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amicus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Amicus Cash Flow From Operations Driver Correlations

Understanding the fundamental principles of building solid financial models for Amicus Therapeutics is extremely important. It helps to project a fair market value of Amicus Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Amicus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Amicus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Amicus Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Accounts Payable	Short Term Investments	Common Stock	Property Plant Equipment	Net Debt	Long Term Debt	Total Current Assets	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Net Receivables	Good Will	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Long Term Debt Total	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.84	-0.61	0.95	0.46	0.56	0.73	0.6	0.5	0.64	0.85	0.51	0.53	-0.35	0.37	0.95	0.7	0.39	0.46	0.68	0.01	0.85	0.52	0.43	0.45
Total Stockholder Equity	0.84		-0.3	0.62	0.7	0.77	0.49	0.44	0.22	0.31	0.7	0.35	0.4	-0.02	0.03	0.77	0.41	0.38	0.42	0.32	0.08	0.67	0.51	0.51	0.13
Retained Earnings	-0.61	-0.3		-0.7	-0.2	-0.17	-0.97	-0.88	-0.89	-0.95	-0.81	-0.24	0.07	0.1	-0.93	-0.75	-0.94	0.33	0.24	-0.92	0.47	-0.8	-0.4	-0.25	-0.95
Total Liab	0.95	0.62	-0.7		0.26	0.36	0.76	0.61	0.59	0.74	0.81	0.53	0.53	-0.49	0.5	0.91	0.77	0.34	0.42	0.78	-0.04	0.82	0.45	0.32	0.57
Accounts Payable	0.46	0.7	-0.2	0.26		0.63	0.32	0.38	0.13	0.15	0.49	0.02	0.04	0.3	0.01	0.41	0.28	0.04	0.07	0.14	0.08	0.43	0.48	0.48	0.09
Short Term Investments	0.56	0.77	-0.17	0.36	0.63		0.32	0.29	0.36	0.28	0.66	0.16	-0.07	0.39	-0.14	0.53	0.31	-0.01	0.01	0.32	0.32	0.55	0.69	0.73	-0.05
Common Stock	0.73	0.49	-0.97	0.76	0.32	0.32		0.9	0.85	0.93	0.87	0.31	0.02	-0.09	0.85	0.83	0.94	-0.21	-0.12	0.89	-0.43	0.85	0.45	0.31	0.89
Property Plant Equipment	0.6	0.44	-0.88	0.61	0.38	0.29	0.9		0.73	0.8	0.8	0.24	-0.11	0.11	0.77	0.67	0.86	-0.32	-0.24	0.77	-0.35	0.73	0.58	0.43	0.9
Net Debt	0.5	0.22	-0.89	0.59	0.13	0.36	0.85	0.73		0.95	0.78	0.2	-0.23	0.05	0.8	0.66	0.84	-0.45	-0.38	0.92	-0.37	0.76	0.48	0.39	0.78
Long Term Debt	0.64	0.31	-0.95	0.74	0.15	0.28	0.93	0.8	0.95		0.84	0.22	-0.04	-0.13	0.86	0.76	0.89	-0.29	-0.2	0.96	-0.42	0.83	0.48	0.38	0.85
Total Current Assets	0.85	0.7	-0.81	0.81	0.49	0.66	0.87	0.8	0.78	0.84		0.25	0.02	0.08	0.57	0.88	0.89	-0.15	-0.07	0.88	-0.07	0.94	0.75	0.65	0.65
Short Term Debt	0.51	0.35	-0.24	0.53	0.02	0.16	0.31	0.24	0.2	0.22	0.25		0.51	-0.48	0.15	0.47	0.27	0.48	0.49	0.22	0.02	0.14	0.17	0.11	0.22
Current Deferred Revenue	0.53	0.4	0.07	0.53	0.04	-0.07	0.02	-0.11	-0.23	-0.04	0.02	0.51		-0.86	-0.11	0.4	-0.07	0.94	0.95	-0.05	0.0	0.13	-0.19	-0.18	-0.12
Net Tangible Assets	-0.35	-0.02	0.1	-0.49	0.3	0.39	-0.09	0.11	0.05	-0.13	0.08	-0.48	-0.86		-0.17	-0.3	-0.01	-0.75	-0.77	-0.09	0.24	-0.06	0.4	0.42	-0.08
Net Receivables	0.37	0.03	-0.93	0.5	0.01	-0.14	0.85	0.77	0.8	0.86	0.57	0.15	-0.11	-0.17		0.54	0.8	-0.39	-0.32	0.8	-0.68	0.59	0.18	0.05	0.94
Good Will	0.95	0.77	-0.75	0.91	0.41	0.53	0.83	0.67	0.66	0.76	0.88	0.47	0.4	-0.3	0.54		0.79	0.21	0.29	0.77	-0.17	0.92	0.45	0.36	0.57
Capital Surpluse	0.7	0.41	-0.94	0.77	0.28	0.31	0.94	0.86	0.84	0.89	0.89	0.27	-0.07	-0.01	0.8	0.79		-0.29	-0.2	0.94	-0.24	0.86	0.54	0.37	0.87
Deferred Long Term Liab	0.39	0.38	0.33	0.34	0.04	-0.01	-0.21	-0.32	-0.45	-0.29	-0.15	0.48	0.94	-0.75	-0.39	0.21	-0.29		0.99	-0.29	0.17	-0.08	-0.25	-0.19	-0.38
Intangible Assets	0.46	0.42	0.24	0.42	0.07	0.01	-0.12	-0.24	-0.38	-0.2	-0.07	0.49	0.95	-0.77	-0.32	0.29	-0.2	0.99		-0.2	0.14	0.01	-0.21	-0.17	-0.31
Long Term Debt Total	0.68	0.32	-0.92	0.78	0.14	0.32	0.89	0.77	0.92	0.96	0.88	0.22	-0.05	-0.09	0.8	0.77	0.94	-0.29	-0.2		-0.25	0.86	0.57	0.43	0.81
Long Term Investments	0.01	0.08	0.47	-0.04	0.08	0.32	-0.43	-0.35	-0.37	-0.42	-0.07	0.02	0.0	0.24	-0.68	-0.17	-0.24	0.17	0.14	-0.25		-0.13	0.22	0.18	-0.5
Short Long Term Debt	0.85	0.67	-0.8	0.82	0.43	0.55	0.85	0.73	0.76	0.83	0.94	0.14	0.13	-0.06	0.59	0.92	0.86	-0.08	0.01	0.86	-0.13		0.55	0.44	0.63
Net Invested Capital	0.52	0.51	-0.4	0.45	0.48	0.69	0.45	0.58	0.48	0.48	0.75	0.17	-0.19	0.4	0.18	0.45	0.54	-0.25	-0.21	0.57	0.22	0.55		0.96	0.33
Net Working Capital	0.43	0.51	-0.25	0.32	0.48	0.73	0.31	0.43	0.39	0.38	0.65	0.11	-0.18	0.42	0.05	0.36	0.37	-0.19	-0.17	0.43	0.18	0.44	0.96		0.15
Capital Stock	0.45	0.13	-0.95	0.57	0.09	-0.05	0.89	0.9	0.78	0.85	0.65	0.22	-0.12	-0.08	0.94	0.57	0.87	-0.38	-0.31	0.81	-0.5	0.63	0.33	0.15

Click cells to compare fundamentals

Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Competition

Predict Amicus Therapeutics

Total Cash From Operating Activities Over Time

In accordance with the recently published financial statements, Amicus Therapeutics has (33.89 Million) in Cash Flow From Operations. This is 106.43% lower than that of the Biotechnology sector and 154.2% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 103.49% higher than that of the company.

Amicus Cash Flow From Operations Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amicus Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amicus Therapeutics could also be used in its relative valuation, which is a method of valuing Amicus Therapeutics by comparing valuation metrics of similar companies.

Amicus Therapeutics is currently under evaluation in cash flow from operations category among its peers.

Amicus Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Amicus Therapeutics from analyzing Amicus Therapeutics' financial statements. These drivers represent accounts that assess Amicus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Amicus Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	6.0B	3.1B	3.5B	4.2B	2.9B	3.0B
Enterprise Value	6.3B	3.3B	3.8B	4.4B	3.1B	3.3B

Amicus Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Amicus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Amicus Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Amicus Fundamentals

	Return On Equity	-0.32
	Return On Asset	0.0272
	Profit Margin	(0.11) %
	Operating Margin	0.11 %
	Current Valuation	2.84 B
	Shares Outstanding	307.24 M
	Shares Owned By Insiders	0.82 %
	Shares Owned By Institutions	99.18 %
	Number Of Shares Shorted	14.74 M
	Price To Earning	(9.18) X
	Price To Book	13.65 X
	Price To Sales	5.05 X
	Revenue	528.29 M
	Gross Profit	475.35 M
	EBITDA	29.39 M
	Net Income	(56.11 M)
	Cash And Equivalents	386.84 M
	Cash Per Share	1.38 X
	Total Debt	443.64 M
	Debt To Equity	2.60 %
	Current Ratio	3.02 X
	Book Value Per Share	0.65 X
	Cash Flow From Operations	(33.89 M)
	Short Ratio	6.57 X
	Earnings Per Share	(0.18) X
	Price To Earnings To Growth	(0.18) X
	Target Price	16.73
	Number Of Employees	499
	Beta	0.69
	Market Capitalization	2.67 B
	Total Asset	785.03 M
	Retained Earnings	(2.74 B)
	Working Capital	356.03 M
	Current Asset	216.6 M
	Current Liabilities	73.62 M
	Net Asset	785.03 M

About Amicus Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Amicus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Amicus Therapeutics Piotroski F Score and Amicus Therapeutics Altman Z Score analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.18)

Revenue Per Share

1.736

Quarterly Revenue Growth

0.301

Return On Assets

0.0272

Return On Equity

(0.32)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amicus Therapeutics Stock Cash Flow From Operations

Amicus Therapeutics Company Cash Flow From Operations Analysis

Operating Cash Flow

EBITDA

-

Taxes

Current Amicus Therapeutics Cash Flow From Operations

Amicus Cash Flow From Operations Driver Correlations

Amicus Cash Flow From Operations Peer Comparison

Amicus Therapeutics Current Valuation Drivers

Amicus Therapeutics ESG Sustainability

Amicus Fundamentals

About Amicus Therapeutics Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY